EISNER AMPER

ALEX'S LEMONADE STAND FOUNDATION

FINANCIAL STATEMENTS

DECEMBER 31, 2021 and 2020



Contents

		<u>Page</u>
ln	dependent Auditors' Report	1
Fi	inancial Statements	
	Statements of financial position as of December 31, 2021 and 2020	3
	Statements of activities and changes in net assets for the years ended December 31, 2021 and 2020	4
	Statements of functional expenses for the years ended December 31, 2021 and 2020	5
	Statements of cash flows for the years ended December 31, 2021 and 2020	7
	Notes to financial statements	8



EisnerAmper LLP

One Logan Square 130 North 18th Street, Suite 3000 Philadelphia, PA 19103 **T** 215.881.8800 **F** 215.881.8801

www.eisneramper.com

INDEPENDENT AUDITORS' REPORT

To the Board of Directors of Alex's Lemonade Stand Foundation

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of Alex's Lemonade Stand Foundation (the "Foundation"), which comprise the statements of financial position as of December 31, 2021 and 2020, and the related statements of activities and changes in net assets, functional expenses, and cash flows for each of the years then ended, and the related notes to the financial statements.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of Alex's Lemonade Stand Foundation as of December 31, 2021 and 2020, and the changes in its net assets and its cash flows for each of the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America ("GAAS"). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Foundation and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern for one year after the date that the financial statements are available to be issued.



EISNER AMPER

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and, therefore, is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- · Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to
 fraud or error, and design and perform audit procedures responsive to those risks. Such
 procedures include examining, on a test basis, evidence regarding the amounts and disclosures in
 the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures
 that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the
 effectiveness of the Foundation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant
 accounting estimates made by management, as well as evaluate the overall presentation of the
 financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control–related matters that we identified during the audit.

EISNERAMPER LLP Philadelphia, Pennsylvania

Eisnerfmper LLP

May 10, 2022



Statements of Financial Position

	December 31,	
	2021	2020
ASSETS	.	* 40 40 7 404
Cash and cash equivalents	\$ 14,999,954	\$ 13,197,131
Investments	6,783,498	6,068,383
Contributions and other receivables, net Inventories	1,548,743	372,403 126,631
Cash and cash equivalents held for endowment	121,328 30,931	7,551
Investments held for endowment	3,282,755	2,942,318
Property and equipment, net	212,962	245,795
Intangible assets, net	179,723	183,750
Other assets	171,225	176,467
	\$ 27,331,119	\$ 23,320,429
LIABILITIES		
Current liabilities:		
Accounts payable and accrued expenses	\$ 929,275	\$ 321,378
Deferred revenue	341,642	391,419
Grants payable	2,859,918	3,628,031
Deferred rent	-	22,253
Paycheck Protection Program ("PPP") loan payable	162,612	
Total current liabilities	4,293,447	4,363,081
Long-term debt:		
PPP loan payable	555,603	
Total liabilities	4,849,050	4,363,081
Commitments		
NET ASSETS		
Without donor restrictions:		
Designated by the Board of Directors for specific purposes Undesignated	1,216,166 15,425,185	1,203,610 12,282,918
Chaocignatoa	10,420,100	12,202,010
Total without donor restrictions	16,641,351	13,486,528
With donor restrictions	5,840,718	5,470,820
Total net assets	22,482,069	18,957,348
	\$ 27,331,119	\$ 23,320,429

Statements of Activities and Changes in Net Assets

Year Ended December 31,

	Net Assets	2021		-	2020	
	Net Assets	Na4 Assats				
	Without Donor Restrictions	Net Assets With Donor Restrictions	Total	Net Assets Without Donor Restrictions	Net Assets With Donor Restrictions	Total
Support and revenue:						
Contributions:						
Lemonade stands and other events	\$ 13,067,934	\$ -	\$ 13,067,934	\$ 7,113,099	\$ -	\$ 7,113,099
Grants and other	6,719,231	1,935,417	8,654,648	5,520,127	1,762,458	7,282,585
Gala and other special events, net cost of direct benefits						
to donors of \$-0- in 2021 and \$198,083 in 2020	1,271,591	-	1,271,591	1,804,987	-	1,804,987
Licenses and royalties	1,580,348	-	1,580,348	1,630,222	-	1,630,222
Merchandise sales, net cost of merchandise						
sold of \$90,883 in 2021 and \$49,362 in 2020	41,137	-	41,137	27,271	-	27,271
Contributed services	227,892	-	227,892	334,342	-	334,342
Interest and dividend income	295,110	121,050	416,160	171,400	63,873	235,273
Realized and unrealized gains on investments, net	282,565	143,577	426,142	646,143	310,093	956,236
Net assets released from restrictions	1,830,146	(1,830,146)		722,471	(722,471)	
	25,315,954	369,898	25,685,852	17,970,062	1,413,953	19,384,015
Expenses:						
Program services:						
Pediatric cancer research	16,400,953	-	16,400,953	9,198,175	-	9,198,175
Public awareness and education	1,231,572	-	1,231,572	1,385,515	-	1,385,515
Family services	935,264	-	935,264	1,228,393	-	1,228,393
Data lab	1,123,240		1,123,240	936,286		936,286
Total program services	19,691,029		19,691,029	12,748,369		12,748,369
Supporting services:						
General and administrative	1,269,235	-	1,269,235	1,429,369	-	1,429,369
Fundraising	1,200,867		1,200,867	1,470,359		1,470,359
Total supporting services	2,470,102	<u>-</u> _	2,470,102	2,899,728	<u> </u>	2,899,728
	22,161,131		22,161,131	15,648,097		15,648,097
Other income:						
Gain on forgiveness of PPP loan payable				615,000		615,000
Change in net assets	3,154,823	369,898	3,524,721	2,936,965	1,413,953	4,350,918
	13,486,528	5,470,820	18,957,348	10,549,563	4,056,867	14,606,430
Net assets at beginning of year	13,466,326	0,470,020	10,001,010			

See notes to financial statements

Statement of Functional Expenses Year Ended December 31, 2021

	Program Services		Supporting Services						
	Pediatric Cancer Research	Public Awareness and Education	Family Services	Data Lab	Subtotal	General and Administrative	Fundraising	Subtotal	Total
Grants to others	\$ 15,862,324	\$ -	\$ 100,000	\$ -	\$ 15,962,324	\$ -	\$ -	\$ -	\$ 15,962,324
Longitudinal database services	52,000	-	-	-	52,000	-	-	-	52,000
Salaries	335,568	730,881	221,432	729,668	2,017,549	706,476	553,153	1,259,629	3,277,178
Payroll taxes and benefits	74,861	159,868	48,419	161,723	444,871	169,773	121,463	291,236	736,107
Consulting	-	1,811	-	1,500	3,311	77,533	705	78,238	81,549
Legal and accounting	-	-	-	-	-	119,944	-	119,944	119,944
Computer/software expense	21,654	27,502	-	61,907	111,063	11,865	8,094	19,959	131,022
Licenses and fees	2,697	6,308	1,921	6,354	17,280	27,868	156,781	184,649	201,929
Office supplies	4,186	9,437	2,860	4,598	21,081	6,482	7,317	13,799	34,880
Travel	492	500	144	3,781	4,917	1,143	4,239	5,382	10,299
Patient and family travel and support	-	-	514,967		514,967				514,967
Symposiums	13,285	-	´ -	-	13,285	-	_	-	13,285
Subscriptions	1,906	36,302	-	8,664	46,872	4,741	298	5,039	51,911
Postage and shipping	837	44,301	15,374	-	60,512	14,115	53,919	68,034	128,546
Printing	-	21,188	11,739	-	32,927	872	64,315	65,187	98,114
Miscellaneous	-	-	-	-	-	1,174	74	1,248	1,248
Promotional materials	-	79,691	-	-	79,691	218	7,386	7,604	87,295
Lemonade stands and other event fundraising support	-	-	-	-		-	145,852	145,852	145,852
Professional services - public relations	-	1,408	-	-	1,408	50		50	1,458
Office rent	21,032	36,636	10,821	52,793	121,282	35,361	29,551	64,912	186,194
Office repairs and maintenance	2,064	4,614	1,530	-	8,208	3,623	3,375	6,998	15,206
Office utilities	2,208	4,278	1,273	4,552	12,311	3,999	3,349	7,348	19,659
Insurance	3,103	6,542	1,902	6,511	18,058	6,265	4,992	11,257	29,315
Telephone	2,099	4,545	1,368	4,529	12,541	4,379	3,448	7,827	20,368
Website services		9,987	1,120	67,624	78,731	· <u>-</u>	18,696	18,696	97,427
Depreciation	637	1,366	394	9,036	11,433	5,742	1,048	6,790	18,223
Amortization		44,407		<u> </u>	44,407	67,612	12,812	80,424	124,831
Total expense included in expense section on the									
statement of activities and changes in net assets	16,400,953	1,231,572	935,264	1,123,240	19,691,029	1,269,235	1,200,867	2,470,102	22,161,131
Plus expenses included with revenue on the statement of activities and changes in net assets:									
Cost of merchandise sold		90,883			90,883				90,883
Total expenses	\$ 16,400,953	\$ 1,322,455	\$ 935,264	\$ 1,123,240	\$ 19,781,912	\$ 1,269,235	\$ 1,200,867	\$ 2,470,102	\$ 22,252,014

See notes to financial statements 5

Statement of Functional Expenses (continued) Year Ended December 31, 2020

Pediatric Cancer Research Pamily Services Data Lab Subtotal Pamily Subtotal Pundraising Subtotal Pundraising Subtotal Pundraising Subtotal Pundraising Subtotal Pundraising Pundraisin
Longitudinal database services 57,917 - - - 57,917 - - 57,917 - - 57,917 Salaries 390,031 857,715 156,363 614,954 2,019,063 739,468 729,593 1,469,061 3,488,124 Payroll taxes and benefits 74,721 166,302 30,867 118,452 390,342 153,450 141,319 294,769 685,111 Consulting - - - - - - 102,224 - 102,224 102,224
Salaries 390,031 857,715 156,363 614,954 2,019,063 739,468 729,593 1,469,061 3,488,124 Payroll taxes and benefits 74,721 166,302 30,867 118,452 390,342 153,450 141,319 294,769 685,111 Consulting - - - - - 102,224 - 102,224 - 102,224
Payroll taxes and benefits 74,721 166,302 30,867 118,452 390,342 153,450 141,319 294,769 685,111 Consulting 102,224 - 102,224 102,224
Consulting 102,224 - 102,224 102,224
Consulting 102,224 - 102,224 102,224
Legal and accounting 224 735 - 224 735 224 735
Computer/software expense 24,413 9,811 - 61,398 95,622 6,259 3,861 10,120 105,742
Licenses and fees 1,903 4,170 775 3,001 9,849 23,235 144,360 167,595 177,444
Office supplies 3,575 8,429 1,501 394 13,899 9,327 6,819 16,146 30,045
Travel 1,675 1,481 - 875 4,031 3,353 11,099 14,452 18,483
Patient and family travel and support 919,116 - 919,116 919,116
Symposiums 48,373 48,373 48,373
Student leadership academy
Subscriptions 337 38,060 - 4,654 43,051 5,150 290 5,440 48,491
Postage and shipping 1,288 31,870 22,496 - 55,654 11,061 58,254 69,315 124,969
Printing - 19,224 5,767 - 24,991 3,750 49,554 53,304 78,295
Miscellaneous - 99 99 1,825 20 1,845 1,944
Promotional materials - 68,377 2,925 450 71,752 3,277 6,963 10,240 81,992
Lemonade stands and other event fundraising support - 293 293 22 41,298 41,320 41,613
Cost of direct benefit to donors
Rent and facility costs 72,884 72,884 72,884 72,884
Professional services - public relations 30,372 30,372 30,372
Office rent 35,580 78,089 14,364 53,408 181,441 69,407 66,396 135,803 317,244
Office repairs and maintenance 360 824 157 - 1,341 690 701 1,391 2,732
Office utilities 2,836 6,222 1,144 4,645 14,847 5,339 5,291 10,630 25,477
Other direct fundraising expense 27,271 27,271 27,271
Insurance 3,142 6,955 1,271 4,947 16,315 5,965 5,913 11,878 28,193
Telephone 2,774 6,102 1,114 4,464 14,454 5,244 5,190 10,434 24,888
Website services - 14,689 - 55,090 69,779 - 23,398 23,398 93,177
Depreciation 1,319 2,907 533 9,554 14,313 11,068 2,472 13,540 27,853
Amortization <u>- 63,896 63,896 44,520 37,041 81,561 145,457</u>
Total expense included in expense section on the
statement of activities and changes in net assets 9,198,175 1,385,515 1,228,393 936,286 12,748,369 1,429,369 1,470,359 2,899,728 15,648,097
Plus expenses included with revenue on the statement of activities and changes in net assets: Special events - cost of direct benefit to donors:
Food and beverages 194,458 194,458 194,458
Entertainment 625 625 625
Noncash prizes 3,000 3,000 3,000
Total special events - cost of direct benefit to donors 198,083 198,083 198,083
Cost of merchandise sold - 49,362 49,362 49,362
Total expenses \$ 9,198,175 \$ 1,434,877 \$ 1,228,393 \$ 936,286 \$ 12,797,731 \$ 1,429,369 \$ 1,668,442 \$ 3,097,811 \$ 15,895,542

See notes to financial statements

Statements of Cash Flows

	Year Ended December 31,		
	2021	2020	
Cash flows from operating activities:			
Change in net assets	\$ 3,524,721	\$ 4,350,918	
Adjustments to reconcile change in net assets to net cash	* -,	, , , , , , , , , ,	
provided by operating activities:			
Depreciation	18,223	27,853	
Amortization	124,831	145,457	
Realized and unrealized gains on investments	(426,142)	(956,236)	
Gain on forgiveness of PPP loan	(120, 1 12)	(615,000)	
Contributions restricted for endowment	(148,434)	(85,187)	
Non-cash contributions of intangible assets	(18,473)	-	
(Increase) decrease in assets:	(10, 110)		
Contributions and other receivables	(1,176,340)	340,172	
Inventories	5,303	5,385	
Other assets	5,242	(41,605)	
Increase (decrease) in liabilities:	V,- :-	(11,000)	
Accounts payable and accrued expenses	607,897	5,497	
Deferred revenue	(49,777)	(200,731)	
Grants payable	(768,113)	(653,122)	
Deferred rent	(22,253)	(22,768)	
	(==,===)	(==,: 55)	
Net cash provided by operating activities	1,676,685	2,300,633	
Cash flows from investing activities:			
Purchase of property and equipment	(87,721)	(32,075)	
Purchase of investments	(1,391,870)	(3,828,831)	
Proceeds from sales of investments	762,460	3,152,194	
		<u> </u>	
Net cash used in investing activities	(717,131)	(708,712)	
Cash flows from financing activities:			
Proceeds from contribution restricted for endowment	148,434	85,187	
Proceeds from PPP loan	718,215	615,000	
Net cash provided by financing activities	866,649	700,187	
Net increase in cash and cash equivalents and restricted cash	1,826,203	2,292,108	
Cash and cash equivalents and restricted cash at beginning of year	13,204,682	10,912,574	
Cash and cash equivalents and restricted cash at end of year	\$ 15,030,885	\$ 13,204,682	

Year Ended

Notes to Financial Statements December 31, 2021 and 2020

NOTE A - NATURE OF ACTIVITIES

Alex's Lemonade Stand Foundation (the "Foundation") was established as a Pennsylvania nonprofit organization on January 17, 2005 for the following purposes:

- To raise funds for pediatric cancer care, treatment and research, including impactful research focused on new cures and treatments.
- To raise public awareness about pediatric cancer.
- To encourage and educate others, especially children, to raise funds for such purposes.
- To provide families with services via support programs to care and ease financial burden of families while
 their children are undergoing treatment for cancer. The Foundation's Travel for Care program helps to
 offset travel expenses for families who must travel to receive potentially lifesaving treatment for a child. In
 addition, the Foundation's SuperSibs program is dedicated to comforting, encouraging, and empowering
 siblings as their brother or sister fights cancer.
- To accelerate the pace of finding cures for childhood cancer by empowering scientists and doctors to harness the power of big data through the data lab. The Foundation's Childhood Cancer Data Lab is dedicated to childhood cancer by translating research data into one consistent format so that all researchers can access and understand.

The Foundation is supported through a mix of community and corporate fundraising events, corporate sponsorships and grants, grants from philanthropic sources and license and merchandising arrangements. Funds are used primarily to support grants to leading research institutions in the United States for pediatric cancer research and clinical trials. Smaller amounts support education and public awareness activities undertaken directly by the Foundation's staff.

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The accompanying financial statements of the Foundation have been prepared using the accrual basis of accounting and conform to accounting principles generally accepted in the United States of America ("U.S. GAAP") as applicable to not-for-profit organizations.

[1] Classification of net assets:

The Foundation reports information regarding its financial position and activities based on the existence or absence of donor-imposed or grantor-imposed restrictions. Accordingly, net assets and changes therein are classified and reported as follows:

Net Assets Without Donor Restrictions - Net assets without donor restrictions represent net assets available for use in general operations and not subject to donor (or certain grantor) restrictions. The Board of Directors has established three Board-designated funds, which include the Spinal Cord Research Fund, Pediatric Oncology Student Training Award Fund, and Fund for the Future.

The Spinal Cord Research Fund is designed for spinal cord research. The Pediatric Oncology Student Training Award Fund and the Fund for the Future are endowment funds that are designated for grants to pediatric oncology students (see Note K).

Notes to Financial Statements December 31, 2021 and 2020

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[1] Classification of net assets: (continued)

Board-designated net assets as of December 31, 2021 and 2020 consist of the following:

	2021	2020
Spinal Cord Research Fund	\$1,000,000	\$1,000,000
Pediatric Oncology Student Training Award Fund	83,778	78,954
Fund for the Future	132,388	124,656
	\$1,216,166	\$1,203,610

Net Assets With Donor Restrictions - Net assets subject to donor-imposed restrictions. Some donor-imposed restrictions are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Other donor-imposed restrictions are perpetual in nature, where the donor stipulates that resources be maintained in perpetuity. Donor-imposed restrictions are released when a restriction expires, that is, when the stipulated time has elapsed, when the stipulated purpose for which the resource was restricted has been fulfilled, or both or through appropriation of endowment income or corpus pursuant to an endowment spending rate policy and are reported in the statements of activities and changes in net assets as net assets released from restrictions. Donor-imposed restrictions which are satisfied in the year of donation, are reported as net assets without donor restrictions.

[2] Use of estimates:

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses, including functional allocations, during the reporting period. Actual results could differ from those estimates.

[3] Cash and cash equivalents, and cash and cash equivalents held for endowment:

Cash and cash equivalents consist of cash accounts at financial institutions and nonbank money market funds. The Foundation considers all highly liquid instruments purchased with original maturities of three months or less to be cash equivalents. Cash and highly liquid financial instruments restricted to endowments that are perpetual in nature, or other long-term purposes are excluded from this definition.

The following table provides a reconciliation of cash, cash equivalents, and such amounts considered to be restricted as to use which include cash and cash equivalents held for endowment that are reported within the statements of financial position that sum to the total of the same such amounts shown in the statements of cash flows:

	2021	2020
Cash and cash equivalents Cash and cash equivalents held for endowment	\$14,999,954 30,931	\$ 13,197,131 7,551
Total cash and cash equivalents and restricted cash shown in the statements of cash flows	\$15,030,885	\$ 13,204,682

Notes to Financial Statements December 31, 2021 and 2020

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[4] Investments:

Investments in equity securities with readily determinable fair values and all investments in debt securities are reported at fair value with gains and losses included in the statements of activities and changes in net assets. Invested cash and investments in money markets are valued at cost which approximates fair value. Dividend and interest income is recorded as earned. Gains and losses on sales of investments are determined using the average cost method. Restricted investment income from investments whose restrictions are satisfied in the same period as the income is recognized is classified as net assets without donor restrictions. Investments received as gifts are initially recorded at fair value at the date of receipt.

The Foundation invests in a professionally-managed portfolio that contains various types of securities (see Note G). Such investments are exposed to market and credit risk. Due to the level of risk associated with such investments, and the level of uncertainty related to changes in the values of such investments, it is at least reasonably possible that the amounts reported in the financial statements could change materially in the near term.

[5] Contributions and other receivables:

Contributions and other receivables are periodically reviewed by management for collectability. Bad debts are provided for on the allowance method based on historical experience and management's evaluation of outstanding contributions and other receivables. Accounts are written off when they are deemed uncollectible. Management has determined that an allowance is not deemed necessary as of December 31, 2021 or 2020.

[6] Inventories:

Inventories consisting of merchandise held for sale are stated at the lower of cost and net realizable value as determined by the average cost method. Net realizable value is defined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation.

[7] Property and equipment and depreciation and amortization:

Property and equipment are stated at cost less accumulated depreciation and amortization. Equipment and other fixed assets in excess of \$5,000 are capitalized and recognized in the statements of financial position. Contributed property and equipment are recorded at fair value at the date of donation. Depreciation and amortization are calculated using the straight-line method over assets' estimated useful lives of three to seven years. Maintenance and repairs are charged to operations when incurred.

Management evaluates the recoverability of the investment in long-lived assets on an ongoing basis and recognizes any impairment in the year of determination. Long-lived assets were tested for impairment as of December 31, 2021 and 2020, and in the opinion of management, there was no impairment. It is reasonably possible that relevant conditions could change in the near term and necessitate a change in management's estimate of the recoverability of these assets.

[8] Intangible assets:

Intangible assets were obtained through the acquisition of a not-for-profit organization on March 1, 2019, which consist of copyrights, book files, marketing materials, trademarks, domain and social media accounts, customer list and contracts with author of books. These intangible assets are being amortized on the straight-line method over ten years in accordance with Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 350.

Notes to Financial Statements December 31, 2021 and 2020

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[8] Intangible assets: (continued)

In 2021, the Foundation received contributions in the form of cryptocurrencies in the amount of \$18,473. These contributions are valued and recorded at the time the contribution is made at the market value. These intangible assets are considered indefinite and therefore are not amortized.

Amortized intangible assets consisted of the following as of December 31, 2021 and 2020:

	December 31,		
	2021	2020	
Gross cost - assets obtained through acquisition Accumulated amortization	\$ 225,000 (63,750)	\$ 225,000 (41,250)	
Net cost - assets obtained through acquisition	161,250	183,750	
Cryptocurrencies	18,473		
Net intangible assets	\$ 179,723	\$ 183,750	

Total amortization of intangible assets was approximately \$22,500 for each of the years ended December 31, 2021 and 2020.

Scheduled amortization of intangible assets as of December 31, 2021 is as follows:

Year Ending December 31,	
2022	\$ 22,500
2023	22,500
2024	22,500
2025	22,500
2026	22,500
Thereafter	48,750
	\$ 161,250

[9] Paycheck Protection Program:

On March 27, 2020, Congress enacted the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act"). The Paycheck Protection Program ("PPP") established by the CARES Act, implemented by the U.S. Small Business Administration ("SBA"), provides businesses, including certain not-for-profit organizations, with funds to pay payroll and other costs during the coronavirus ("COVID-19") outbreak. During fiscal years 2021 and 2020, the Foundation applied for and received PPP funds. The Foundation has elected to record the PPP funds as a loan under FASB ASC 470, *Debt*. Loan forgiveness will be recognized when the conditions for loan forgiveness are met and the forgiveness amount is formally approved by the bank and the SBA. The PPP loan is more fully described in Note I.

Notes to Financial Statements December 31, 2021 and 2020

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[10] Revenue recognition - contributions:

Funding for the Foundation's activities is achieved almost entirely through contributions made through lemonade stands and other events, and grants, including unconditional promises to give. These donations provide funding to be used to support the mission of the Foundation. As the donors are not receiving a benefit as a result of these transactions, the donations are considered to be contributions to the Foundation. Some contributions require that funds be expended for a specific purpose, and are considered to be net assets with donor restrictions.

The Foundation recognizes contributions as revenue when cash, securities or other assets, an unconditional promise to give, or a notification of a beneficial interest is received. Conditional promises to give - that is, those with a measurable performance or other barrier and a right of return - are not recognized until the conditions on which they depend have been met.

The Foundation records special events revenue equal to the cost of direct benefits to donors, and contribution revenue for the difference, which is included in gala and special events on the statements of activities and changes in net assets. The recognition of revenue is conditional on the event taking place, as this is the point in time when the performance obligation of hosting the event occurs, and attendees can no longer request a refund for their tickets purchased. As of December 31, 2021 and 2020, there were conditional contributions associated with special events of \$341,642 and \$391,419, respectively, that were included in deferred revenue. Amounts will be recognized as revenue when such events occur.

The CARES Act provides an employee retention credit ("CARES Employee Retention credit"), which is a refundable tax credit against certain employment taxes. From March 12, 2020 through December 31, 2020, the tax credit is equal to 50% of qualified wages up to \$10,000 or a maximum credit of up to \$5,000 per employee. From January 1, 2021 through June 30, 2021, the tax credit is equal to 70% of qualified wages up to \$10,000 during a quarter or a maximum credit of up to \$14,000 per employee (or \$7,000 per quarter). During the fiscal year ended December 31, 2021, the Foundation recorded \$1,014,907 related to the CARES Employee Retention credit in grants and other contributions revenue on the Foundation's statements of activity and changes in net assets. As of December 31, 2021, the Foundation has a \$1,014,907 receivable balance from the United States government related to the CARES Act, which is recorded in contributions and other receivables on the Foundation's statements of financial position.

[11] Revenue recognition - services:

Licenses and royalties:

Licenses and royalties revenue reflects royalties generated by the use of the Foundation's name and logo by third parties. Revenue is reported based on license and royalty agreements between the Foundation and third parties. Revenue is recognized at a point in time when the Foundation is notified by the third parties that a sale and/or usage occurred of the licensed merchandise.

Merchandise sales:

Merchandise sales consist of items sold on the Foundation's website, such as apparel and accessories. Merchandise revenue is recognized at a point in time when the merchandise is shipped to the customer, as this is when the performance obligation has been satisfied by transferring the control of the goods to the customer. The amount recognized is the amount that reflects the consideration expected to be received in exchange for providing the merchandise. Customers are charged upon placing the order.

Notes to Financial Statements December 31, 2021 and 2020

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[12] Contributed services:

The Foundation recognizes contributions of services received if such services (a) create or enhance nonfinancial assets, or (b) require specialized skills, are provided by individuals possessing those skills and would typically need to be purchased if not contributed.

During 2021, the Foundation received contributed services of \$227,892, which consists of \$36,503 for investment advisory services, \$54,091 for legal services, \$77,398 for shipping services and \$59,900 for IT software, which are included in general and administrative expenses in the accompanying statement of activities and changes in net assets.

During 2020, the Foundation received contributed services of \$334,342, which consists of \$32,194 for investment advisory services, \$163,191 for legal services, and \$79,057 for shipping services and \$59,900 for IT software, which are included in general and administrative expenses in the accompanying statement of activities and changes in net assets.

In addition, the Foundation receives services from a large number of volunteers who give significant amounts of their time to the Foundation's administration and management, fundraising, and education and public awareness program services. No amounts have been included for these types of donated services, as they do not meet the criteria outlined above.

[13] Grants payable:

The Foundation's grant spending is approved by the Foundation's Board of Directors. The Foundation has established scientific advisory and review boards to review grant applications. The scientific boards makes grant recommendations, based upon the Foundation's guidelines and criteria, to the Foundation's Executive Directors who have final authority over grant-making decisions. The Foundation records grants payable when the grants are approved by the Foundation's Executive Directors, which is when the Foundation considers the grant awards to be unconditionally promised. A grant is deemed to be conditional if it includes one or more measurable barriers and a right of return or forfeiture. All grant liabilities as of December 31, 2021 and 2020 are payable within one year of the respective statements of financial position dates.

Conditional commitments and intentions to award grants to others are not recorded as an expense until the measurable barriers have been met (see Note N).

[14] Functional allocation of expenses:

Directly identifiable expenses are charged to program services, general and administrative, and fundraising. Salaries, payroll taxes, and benefits are charged to the different functions based on the employees' actual functions performed. Expenses related to more than one function are allocated among the functions benefited, as follows: computer/software expense, licenses and fees, office supplies, travel, office rent, office repairs and maintenance, office utilities, insurance, telephone, depreciation, and amortization - based on employee gross salaries or estimates of time and effort depending on the employee's function.

[15] Costs of direct benefit to donors:

The Foundation conducts special events in which a portion of the gross proceeds paid by the participant represents payment for the direct costs of the benefits received by the participant at the event. The direct costs of the special events which ultimately benefit the donor is netted with gala and other special events on the statements of activities and changes in net assets. During the year ended December 31, 2021 there were no cost of direct benefit to donors.

Notes to Financial Statements December 31, 2021 and 2020

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[16] Income taxes:

The Internal Revenue Service has classified the Foundation as exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code ("Code"); as an organization, contributions to which are deductible under Section 170(c) of the Code; and as an organization that is not a private foundation as defined in Section 509(a) of the Code.

U.S. GAAP requires management to evaluate tax positions taken and recognize a tax liability, if the Foundation has taken an uncertain tax position that more likely than not would not be sustained upon examination by a government authority. Management has analyzed the tax positions taken by the Foundation and has concluded that as of December 31, 2021 and 2020, there are no uncertain positions taken or expected to be taken that would require recognition of a liability or disclosure in the financial statements.

The Foundation recognizes accrued interest and penalties associated with uncertain tax positions, if any. There were no income tax related interest and penalties recorded for either of the years ended December 31, 2021 or 2020.

[17] Advertising and promotional costs:

Advertising and promotional costs are expensed in the year incurred. Advertising expense for the years ended December 31, 2021 and 2020 was \$87,295 and \$81,992, respectively.

[18] Upcoming accounting pronouncement:

In February 2016, FASB issued Accounting Standards Update ("ASU") No. 2016-02, *Leases (Topic 842)*. The standard's core principle is to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the statement of financial position and disclosing key information. ASU 2016-02 will be effective for nonpublic entities for fiscal years beginning after December 15, 2021, with early adoption permitted. Management is currently evaluating the effect that this new guidance will have on its financial statements and related disclosures.

Notes to Financial Statements December 31, 2021 and 2020

NOTE C - LIQUIDITY AND AVAILABILITY

Financial assets available for general expenditure, that is, without donor or other restrictions limiting their use, within one year of the statements of financial position date, comprise the following as of December 31, 2021 and 2020:

	December 31,	
	2021	2020
Financial assets:		
Cash and cash equivalents	\$ 14,999,954	\$ 13,197,131
Investments	6,783,498	6,068,383
Contributions and other receivables	1,548,743	372,403
Cash and cash equivalents held for endowment	30,931	7,551
Investments held for endowment	3,282,755	2,942,318
Total financial assets	26,645,881	22,587,786
Less amounts not available to be used within one year: Net assets with donor restrictions subject to expenditures for		
specified purposes Net assets with donor restrictions subject to the Foundation's	387,301	521,765
spending policy and appropriation	3,097,520	2,746,259
Board-designated for specific purpose	1,216,166	1,203,610
	4,700,987	4,471,634
Financial assets available to meet cash needs for general expenditures within one year	\$ 21,944,894	\$ 18,116,152

General expenditures include program services expenses, general and administrative expenses, and fundraising expenses expected to be paid in the subsequent year.

The Foundation's total investments consist of operating investments, donor-restricted endowments and funds designated by the Board as endowments. Income from donor-restricted endowments is restricted for specific purposes. Donor-restricted endowment funds of \$3,097,520 and \$2,746,259 as of December 31, 2021 and 2020, respectively, are not available for general expenditure.

The Foundation evaluates its endowment spending policy for the next fiscal year after the second quarter results of that year. In the third quarter of that year, the Board of Directors determine its election on the endowment spending policy.

With the exception of the net assets with donor restrictions relating to spinal cord research of \$387,301 and \$521,765 as of December 31, 2021 and 2020, respectively, net assets with donor restrictions subject to expenditures for specified purposes are expected to be released in 2022.

As part of the Foundation's liquidity management plan, the Foundation structures its financial assets to be available as its general expenditures, liabilities, and other obligations come due. In addition, the Foundation invests cash in excess of daily requirements in money market funds and other short-term investments.

Notes to Financial Statements December 31, 2021 and 2020

NOTE D - CONTRIBUTIONS AND OTHER RECEIVABLES

Contributions and other receivables, which are receivable in more than one year, are discounted at a risk-free rate of return appropriate for the expected term of the promise to give, and approximate the net present value of the estimated future cash flows. In determining fair value, the Foundation considers the creditworthiness of the donors, the Foundation's past collection experience and its procedures to collect promises to give.

Contributions, pledges and grants receivable as of December 31, 2021 and 2020 are as follows:

	2021	2020
Less than one year One year to five years	\$1,311,674 252,500	\$ 150,693 245,000
Total receivables	1,564,174	395,693
Less: total discounts to net present value	15,431	23,290
Total net receivables	\$1,548,743	\$ 372,403

Pledges which are receivable in more than one year are discounted at rates ranging from 2.58% to 2.69%.

NOTE E - CONCENTRATION OF CREDIT RISK

The Foundation maintains cash in various financial institutions with insurance provided by the Federal Deposit Insurance Corporation up to \$250,000. The Foundation also maintains cash and cash equivalents in various nonbank money market funds that are uninsured. As of December 31, 2021 and 2020, the Foundation has uninsured balances of approximately \$13,834,000 and \$12,049,000, respectively.

NOTE F - INVESTMENTS

Investments consist of the following as of December 31, 2021 and 2020:

	2021	2020
Investments: Mutual funds:		
Equity funds	\$ 2,812,098	\$ 2,425,083
Bond funds	2,411,954	2,286,272
Exchange-traded funds	1,559,446	1,357,028
-		
	6,783,498	6,068,383
Investments restricted for endowment: Mutual funds:		
Equity funds	1,221,129	1,047,891
Bond funds	1,160,214	1,106,573
Exchange-traded funds	901,412	787,854
	3,282,755	2,942,318
	\$10,066,253	\$ 9,010,701

Notes to Financial Statements December 31, 2021 and 2020

NOTE G - FAIR VALUE MEASUREMENTS

The fair value of each investment is determined at the statement of financial position date in accordance with FASB ASC Topic 820, *Fair Value Measurements and Disclosures*. Accordingly, fair value refers to the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between participants in the market in which the reporting entity transacts, and fair value measurements are separately disclosed by level within the fair value hierarchy.

Investments measured and reported at fair value are classified and disclosed in one of the following categories:

Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2 – Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in inactive markets; or inputs that are derived principally from or corroborated by observable market data.

Level 3 – Unobservable inputs that are supported by little or no market activity and are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or other valuation techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.

The financial instruments within the fair value hierarchy are based on the lowest level of any input that is significant to the fair value measurement. The valuation levels are not necessarily an indication of the risk or liquidity associated with the underlying assets and liabilities.

The following is a description of the valuation methodology used for instruments measured at fair value. This valuation methodology was applied to all of the Foundation's assets and liabilities that are carried at fair value as of December 31, 2021 and 2020.

Mutual funds - the fair value of securities is the market value based on quoted market prices in a market deemed to be active, when available, or market prices provided by recognized broker dealers (Level 1).

The following tables set forth, by level, the Foundation's investments at fair value, within the aforementioned fair value hierarchy, as of December 31, 2021 and 2020:

Investment Assets at Fair Value as of December 31, 2021

	December 51, 2021					
	Total	Level 1	Leve	el 2	Lev	el 3
Mutual funds:						
Equity funds	\$ 4,033,227	\$ 4,033,227	\$	-	\$	-
Bond funds	3,572,168	3,572,168		-		-
Exchange-traded funds	2,460,858	2,460,858				
Total investment assets at fair value	\$ 10,066,253	\$ 10,066,253	\$		\$	

Notes to Financial Statements December 31, 2021 and 2020

NOTE G - FAIR VALUE MEASUREMENTS (CONTINUED)

Investment	Assets	at Fair	Value	as	of
------------	--------	---------	-------	----	----

	December 31, 2020					
	Total	Level 1	Level 2		Level 3	
Mutual funds:						
Equity funds	\$ 3,472,974	\$ 3,472,974	\$	-	\$	-
Bond funds	3,392,845	3,392,845		-		-
Exchange-traded funds	2,144,882	2,144,882				
Total investment assets at fair value	\$ 9,010,701	\$ 9,010,701	\$		\$	

Changes in fair value levels:

The availability of observable market data is monitored to assess the appropriate classification of financial instruments within the fair value hierarchy. Changes in economic conditions or model-based valuation techniques may require the transfer of financial instruments from one fair value level to another. In such instances, the transfer is reported at the beginning of the reporting period. For the years ended December 31, 2021 and 2020, there were no transfers into or out of Levels 1, 2 or 3.

NOTE H - PROPERTY AND EQUIPMENT

Property and equipment as of December 31, 2021 and 2020 consist of the following:

	2021	2020
Equipment and vehicle Software and website development	\$ 341,259 1,240,534	\$ 284,558 1,209,514
Less accumulated depreciation and amortization	1,581,793 1,368,831	1,494,072 1,248,277
	\$ 212,962	\$ 245,795

Depreciation for the years ended December 31, 2021 and 2020 was \$18,223 and \$27,852, respectively. Amortization of software and website development for the years ended December 31, 2021 and 2020 was \$102,331 and \$122,957, respectively.

NOTE I - PAYCHECK PROTECTION PROGRAM LOAN

In May 2021 and April 2020, the Foundation received loans for \$718,215 and \$615,000, respectively, pursuant to the CARES Act PPP. These loans may be forgiven subject to bank approval in accordance with the SBA guidelines. The loan is to be used for qualified expenses and to maintain certain employment levels. Neither principal nor interest is due until the earlier of the determination of loan forgiveness, if forgiveness is denied, or seven months after the end of the forgiveness period which is expected to be November 2021 and October 2020, respectively. If forgiveness has been applied for but not approved by November 2021 and October 2020, respectively, the deferral period is to be extended until such time as the forgiveness application is either approved or denied. The Foundation is in the process of applying for forgiveness for the loan received in May 2021 and is awaiting formal approval by the bank and SBA. If the loan is either denied or forgiveness not applied for, the loan will convert to a term loan with an interest rate of 1%. Monthly payments of principal and interest would commence with all outstanding principal and interest due at maturity in May 2026.

Notes to Financial Statements December 31, 2021 and 2020

NOTE I - PAYCHECK PROTECTION PROGRAM LOAN (CONTINUED)

Scheduled maturities of PPP loan as of December 31, 2021 are as follows:

Year Ending December 31,	
2022	\$162,612
2023	162,612
2024	162,612
2025	162,612
2026	67,767
	_ \$718,215

For the loan received in April 2020, the Foundation received notification from the SBA on December 18, 2020 that the full amount of the PPP loan was forgiven and would not have to be repaid. For the year ended December 31, 2021, \$615,000 of the grant was recognized as gain on forgiveness of PPP loan payable on the statement of activities and changes in net assets.

NOTE J - NET ASSETS WITH DONOR RESTRICTIONS

Net assets with donor restrictions are restricted for the following purposes or period as of December 31, 2021 and 2020:

	2021	2020
Subject to expenditures for specified purpose: Crazy 8 research initiative	\$ -	\$ 121,642
	•	· ·-·,· ·-
Spinal cord research	387,301	521,765
Target research grants	453,395	881,770
Travel for care program	644,327	572,088
Other cancer research	1,258,175	627,296
	2,743,198	2,724,561
Endowments:		
Subject to appropriation and expenditure when		
a specified event occurs:		
Restricted by donors for:		
Pediatric oncology student training	93,363	72,904
Travel for care program	744,112	561,744
marenter care program		
	837,475	634,648
Perpetual in nature, earnings from which are subject to		
endowment spending policy and appropriation:		
Investments in perpetuity:		
Pediatric oncology student training	223,283	173,061
Travel for care program	2,036,762	1,938,550
	2,260,045	2,111,611
Total endowments	2 007 520	2 746 250
iotai endowinents	3,097,520	2,746,259
	\$ 5,840,718	\$ 5,470,820

Notes to Financial Statements December 31, 2021 and 2020

NOTE J - NET ASSETS WITH DONOR RESTRICTIONS (CONTINUED)

Net assets were released from donor restriction by incurring expenses satisfying the restricted purpose specified by the donors as follows for the years ended December 31, 2021 and 2020:

	2021	2020	
Satisfaction of purpose restrictions:			
Crazy 8 research initiative	\$ 121,643	\$ -	
Spinal cord research	196,183	-	
Target research grants	753,375	214,903	
Travel for care program	351,177	214,462	
Other cancer research	345,968	225,106	
	1,768,346	654,471	
Restricted purpose spending-rate distributions and appropriations:			
Pediatric oncology student training	8,200	9,500	
Travel for care program	53,600	58,500	
	61,800	68,000	
	\$ 1,830,146	\$ 722,471	

NOTE K - BOARD-DESIGNATED AND DONOR-RESTRICTED ENDOWMENTS

The Foundation has a Board-designated endowment consisting of two basic funds: Pediatric Oncology Student Training Award Fund and Fund for the Future. The Foundation also has donor-restricted endowment funds that are included in nets assets with donor restrictions.

The Foundation's donor-restricted endowments consist of five funds: Rita's Fund for Hope, Shirley Stein POST Award Fund, David Cohn Fund for the Future, Bellin Travel Fund, and Michael and Rosemary Gillet Fund for Early Career Childhood Cancer Scientists. These endowments were established to support the Foundation's pediatric oncology student training and travel for care program. As required by U.S. GAAP, net assets associated with endowment funds, including funds designated by the Board of Directors for endowment, are classified based on the existence or absence of donor-imposed restrictions.

[1] Interpretation of relevant law:

The Commonwealth of Pennsylvania has not adopted Uniform Prudent Management of Institutional Funds Act ("UPMIFA"). State law allows nonprofit organizations to make an election to adopt a total return investment policy as provided by Act 141 (1988) of Pennsylvania legislature, 15 Pa. C.S.A. Section 5548 ("total return election"). The Foundation did not make a total return election; therefore, the Foundation is permitted to spend interest and dividends.

Notes to Financial Statements December 31, 2021 and 2020

NOTE K - BOARD-DESIGNATED AND DONOR-RESTRICTED ENDOWMENTS (CONTINUED)

[2] Return objectives and risk parameters:

Endowment assets include those assets of donor-restricted funds that the Foundation must hold in perpetuity as well as Board-designated funds. Accordingly, the investment objective is the preservation of capital as well as providing a predictable stream of funding to the program supported by its endowments without bearing risk of market fluctuation.

[3] Strategies employed for achieving objectives:

To satisfy its long-term rate-of-return objectives, the Foundation relies on a strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). As a result, the Foundation has elected to adopt an asset allocation consisting of equity and fixed-income securities. The Foundation's current asset allocation for endowment funds targets a composition of approximately 60% in equity mutual funds and 40% in fixed-income mutual funds.

[4] Spending policy:

In accordance with donor instructions, earnings on the donor-restricted endowments are considered restricted; as such, earnings may only be used for the program purpose specified by the donors. Interest and dividend income on the funds' investments is appropriated as determined by the Board of Directors. The Foundation has adopted a formal spending policy. During the years ended December 31, 2021 and 2020, it was elected by the Board to appropriate 4% and 5%, respectively, based on a four-year moving average market value, of the endowments based on June 30 point valuations (subject to annual review).

[5] Funds with deficiencies:

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the original gift (underwater endowments). Such deficiencies are recorded as net assets with donor restrictions. In the event that an endowment fund is underwater, all income and distributions will be reinvested into the endowment fund until the market value of the endowment fund has recovered. As of December 31, 2021 and 2020, there were no deficiencies of this nature.

Endowment funds as of December 31, 2021 and 2020 comprise the following:

	2021				
	Net Assets Without Donor Restriction	With Donor	Total		
Board-designated endowment funds:					
Pediatric Oncology Student Training Award Fund	\$ 83,778	3 \$ -	\$ 83,778		
Fund for the Future	132,388	-	132,388		
Donor-restricted endowment funds:					
Original donor-restricted gift amount		- 2,260,045	2,260,045		
Accumulated investment gains		837,475	837,475		
	\$ 216,166	\$ 3,097,520	\$ 3,313,686		
Pediatric Oncology Student Training Award Fund Fund for the Future Donor-restricted endowment funds: Original donor-restricted gift amount	\$ 83,778 132,388	Restrictions 3	\$ 83,778 132,388 2,260,045 837,475		

Notes to Financial Statements December 31, 2021 and 2020

NOTE K - BOARD-DESIGNATED AND DONOR-RESTRICTED ENDOWMENTS (CONTINUED)

[5] Funds with deficiencies: (continued)

	2020				
	Net Assets Without Donor Restrictions	Net Assets With Donor Restrictions	Total		
Board-designated endowment funds: Pediatric Oncology Student Training Award Fund	\$ 78,954	\$ -	\$ 78,954		
Fund for the Future Donor-restricted endowment funds:	124,656	-	124,656		
Original donor-restricted gift amount	-	2,111,611	2,111,611		
Accumulated investment gains		634,648	634,648		
	\$ 203,610	\$ 2,746,259	\$2,949,869		

The Foundation's endowments had the following activity for the years ended December 31, 2021 and 2020:

	2021					
	Net Assets Without					
	Donor Restrictions	Net Assets	With Donor Re	strictions		
	Ttooti Iotiono	Subject	Perpetual	<u> </u>		
	Board -	to	in			
	Designated	Appropriation	Nature	Subtotal	Total	
Endowment net assets at beginning of year	\$ 203,610	\$ 634,648	\$ 2,111,611	\$ 2,746,259	\$ 2,949,869	
Investment return, net	12,556	264,627	-	264,627	277,183	
Contributions	-	-	148,434	148,434	148,434	
Appropriation of endowment assets pursuant to spending-rate policy		(61,800)		(61,800)	(61,800)	
Change in net assets	12,556	202,827	148,434	351,261	363,817	
Endowment net assets at end of year	\$ 216,166	\$ 837,475	\$ 2,260,045	\$ 3,097,520	\$ 3,313,686	

Notes to Financial Statements December 31, 2021 and 2020

NOTE K - BOARD-DESIGNATED AND DONOR-RESTRICTED ENDOWMENTS (CONTINUED)

[5] Funds with deficiencies: (continued)

	2020					
	Net Assets Without Donor Restrictions	Net Assets	: With Donor Re	strictions		
	Board - Designated	Subject to Appropriation	Perpetual in Nature	Subtotal	Total	
Endowment net assets at beginning of year	\$ 181,704	\$ 328,008	\$ 2,026,424	\$ 2,354,432	\$ 2,536,136	
Investment return, net	21,906	374,640	-	374,640	396,546	
Contributions	-	-	85,187	85,187	85,187	
Appropriation of endowment assets pursuant to spending-rate policy		(68,000)		(68,000)	(68,000)	
Change in net assets	21,906	306,640	85,187	391,827	413,733	
Endowment net assets at end of year	\$ 203,610	\$ 634,648	\$ 2,111,611	\$ 2,746,259	\$ 2,949,869	

NOTE L - RETIREMENT PLAN

The Foundation offers eligible employees the opportunity to participate in a Simple IRA plan whereby employees may elect to contribute up to 100% of their income on a pre-tax basis, subject to limitations specified by the Internal Revenue Code. The Foundation matches each employee's contribution on a one-to-one basis, up to 3% of compensation. From July 2020 to December 2020, management opted to temporarily suspend matching contributions to plan participants. The Foundation made matching contributions into the plan of \$78,934 and \$43,109 during the years ended December 31, 2021 and 2020, respectively.

NOTE M - OPERATING LEASE

On December 31, 2013, the Foundation entered into an operating lease agreement for office and storage space. The lease term is for 85 months, beginning on April 28, 2014, with the option to renew for one additional three-year period. On May 4, 2015, the Foundation amended the operating lease agreement for the office and storage space for additional office space.

On November 2, 2018, the Foundation entered into an operating lease for office space. The term is for 38 months, beginning on January 1, 2019.

On October 1, 2021, the Foundation entered into an operating lease for office space. The term is for 53 months, beginning on February 1, 2022. In addition, the Foundation entered into a lease agreement for storage space in the same office building on October 1, 2021. The term is for 56 months, beginning October 1, 2021.

Notes to Financial Statements December 31, 2021 and 2020

NOTE M - OPERATING LEASE (CONTINUED)

Scheduled future minimum lease payments as of December 31, 2021 are as follows:

Year Ending December 31,	
2022	\$ 229,913
2023	336,812
2024	346,090
2025	355,382
2026	 180,650
	\$ 1,448,847

Rent expense for the years ended December 31, 2021 and 2020 was \$186,194 and \$317,245, respectively. Rent expense includes the allocation of rent based on a straight-line amortization of the total rent payments due under the lease over the term of the lease. The cumulative difference between the rent expense on a straight-line basis and actual rent payments made is recorded as deferred rent on the statements of financial position.

NOTE N - CONDITIONAL COMMITMENTS

The Foundation has conditional commitments to fund various medical research grants. The future funding of the grants is conditional upon a noncompetitive review and demonstration of satisfactory completion of proposed research objectives and appropriate budget expenditures and, therefore, the conditional future payments are not recorded in the financial statements. Conditional commitments for future grant payments as of December 31, 2021 are as follows:

Year Ending December 31,	
2022	\$ 12,160,862
2023	8,708,405
2024	5,904,809
2025	1,880,050
	\$ 28,654,126

NOTE O - CONTINGENCIES AND OTHER UNCERTAINTIES

The Foundation is actively monitoring the impact of the coronavirus, government actions related to it and the possible impact on our operations. To date, we have seen a need to restructure a portion of our fundraising efforts and we have also utilized the government assistance measures to mitigate some of the impact, resulting in improved revenues in 2021 compared to 2020. The Foundation has developed alternative strategies and has a plan to grow revenues over the next several years, while continuing to prioritize funding pediatric cancer research.

NOTE P - SUBSEQUENT EVENTS

The Foundation has evaluated subsequent events through May 10, 2022, which is the date the financial statements were available to be issued.